US › Healthcare

Alzamend Neuro Inc (ALZN)

US · Healthcare · Biotechnology

$1.45+8.21%

Last close · 2026-08-04

Latest quarter · ended 2026-04-30

Revenue

Net profit

$-2.9M

Profit YoY

-151.9%

EPS

$-0.74

EPS estimate

$-0.67

EPS came in at -0.74 against a street estimate of -0.67 — a miss of 10.4%.

Key statistics

Market cap

$6.4M

Forward P/E

0.0

P/B

8.56

Book value

$0.17

EPS (TTM)

$-2.63

52-week high

$2.68

52-week low

$0.84

50-day MA

$1.21

200-day MA

$1.71

Beta

0.19

Analyst view

Analysts rate Alzamend Neuro Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $25.00.

Shareholding

Insiders

2.68%

Institutions

2.41%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	1.20%
Vanguard Group Inc	0.57%
Vanguard Fiduciary Trust Co	0.55%
Morgan Stanley - Brokerage Accounts	0.47%
Hartland & Co	0.26%
Tower Research Capital LLC	0.16%
Citigroup Inc	0.14%
UBS Group AG	0.12%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Alzamend Neuro Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.